The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00488631




Registration number
NCT00488631
Ethics application status
Date submitted
18/06/2007
Date registered
20/06/2007
Date last updated
26/04/2016

Titles & IDs
Public title
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
Scientific title
A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Secondary ID [1] 0 0
2006-003399-37
Secondary ID [2] 0 0
CR014179
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Colitis, Ulcerative 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Placebo
Other interventions - Golimumab 50 mg
Other interventions - Golimumab 100 mg
Other interventions - Golimumab 200 mg

Placebo Comparator: Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance - Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to placebo subcutaneous (under the skin) injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.

Experimental: GLM-I-Rsp-Golimumab 50 mg Maintenance - Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 50 mg or 100 mg subcutaneous injections every 4 weeks through Week 52.

Experimental: GLM-I-Rsp-Golimumab 100 mg Maintenance - Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 100 mg or 200 mg subcutaneous injections every 4 weeks through Week 52.

Placebo Comparator: Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance - Participants in clinical response to placebo at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized. Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.

Experimental: PBO-I-nonRsp-Golimumab 100 mg Maintenance - Participants not in clinical response to placebo at Week 6 induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.

Experimental: GLM-I-nonRsp-Golimumab 100 mg Maintenance - Participants not in clinical response to golimumab at Week 6 of induction study and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.


Other interventions: Placebo
Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).

Other interventions: Golimumab 50 mg
Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).

Other interventions: Golimumab 100 mg
Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.

Other interventions: Golimumab 200 mg
Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants in Clinical Response Through Week 54
Timepoint [1] 0 0
Induction Baseline, Week 0 through Week 54
Secondary outcome [1] 0 0
Number of Participants With Clinical Remission at Both Week 30 and Week 54
Timepoint [1] 0 0
Week 30 and Week 54
Secondary outcome [2] 0 0
Number of Participants With Mucosal Healing at Both Week 30 and Week 54
Timepoint [2] 0 0
Week 30 and Week 54
Secondary outcome [3] 0 0
Number of Participants With Clinical Remission at Both Week 30 and 54 Among Participants With Clinical Remission at Week 0 of Maintenance Study
Timepoint [3] 0 0
Week 30 and Week 54
Secondary outcome [4] 0 0
Number of Participants With Clinical Remission at Week 54 and Not Receiving Concomitant Corticosteroids Among Participants on Corticosteroids at Week 0 of Maintenance Study
Timepoint [4] 0 0
Week 54

Eligibility
Key inclusion criteria
- Participants who received all study agent administrations and completed the Week 6
Mayo score evaluation in induction study C0524T16 (NCT00488774) or C0524T17
(NCT00487539)

- Participants who completed the Week 0 visit for this maintenance study C0524T18
(NCT00488631) on the same day as the Week 6 visit of the induction study C0524T16
(NCT00488774) or C0524T17 (NCT00487539)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Participants who increased the dose of their concomitant (given at the same time) UC
medications since Week 0 of induction study C0524T16 (NCT00488774) or C0524T17
(NCT00487539)

- Participants who initiated a concomitant UC medication since Week 0 of an induction
study C0524T16 (NCT00488774) or C0524T17 (NCT00487539)

- Participants who had a partial or total colectomy (surgery to remove part or all of
the colon) or an ostomy (surgical construction of an artificial opening (stoma) for
external fistulization of a duct or vessel by insertion of a tube with or without a
supportive stent) since Week 0 of an induction study C0524T16 (NCT00488774) or
C0524T17 (NCT00487539)

- Participants with signs or symptoms of latent or active granulomatous infection
(including TB); a nontuberculous mycobacterial infection or opportunistic infection;
or infection with HIV (Human Immunodeficiency Virus), hepatitis B, or hepatitis C

- Participants with signs and symptoms of any malignancy or suggestive of a possible
lymphoproliferative disease (disorders characterized by proliferation of lymphoid
tissue, general or unspecified)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Adelaide
Recruitment hospital [2] 0 0
- Bankstown
Recruitment hospital [3] 0 0
- Box Hill
Recruitment hospital [4] 0 0
- Brisbane
Recruitment hospital [5] 0 0
- Cairns
Recruitment hospital [6] 0 0
- Fitzroy
Recruitment hospital [7] 0 0
- Fremantle
Recruitment hospital [8] 0 0
- Herston
Recruitment hospital [9] 0 0
- Launceston
Recruitment hospital [10] 0 0
- Malvern
Recruitment hospital [11] 0 0
- Parkville
Recruitment hospital [12] 0 0
- Prahran
Recruitment hospital [13] 0 0
- Westmead
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Bankstown
Recruitment postcode(s) [3] 0 0
- Box Hill
Recruitment postcode(s) [4] 0 0
- Brisbane
Recruitment postcode(s) [5] 0 0
- Cairns
Recruitment postcode(s) [6] 0 0
- Fitzroy
Recruitment postcode(s) [7] 0 0
- Fremantle
Recruitment postcode(s) [8] 0 0
- Herston
Recruitment postcode(s) [9] 0 0
- Launceston
Recruitment postcode(s) [10] 0 0
- Malvern
Recruitment postcode(s) [11] 0 0
- Parkville
Recruitment postcode(s) [12] 0 0
- Prahran
Recruitment postcode(s) [13] 0 0
- Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Delaware
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Iowa
Country [11] 0 0
United States of America
State/province [11] 0 0
Kansas
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Maryland
Country [15] 0 0
United States of America
State/province [15] 0 0
Massachusetts
Country [16] 0 0
United States of America
State/province [16] 0 0
Michigan
Country [17] 0 0
United States of America
State/province [17] 0 0
Minnesota
Country [18] 0 0
United States of America
State/province [18] 0 0
Mississippi
Country [19] 0 0
United States of America
State/province [19] 0 0
Missouri
Country [20] 0 0
United States of America
State/province [20] 0 0
Nevada
Country [21] 0 0
United States of America
State/province [21] 0 0
New Hampshire
Country [22] 0 0
United States of America
State/province [22] 0 0
New Jersey
Country [23] 0 0
United States of America
State/province [23] 0 0
New York
Country [24] 0 0
United States of America
State/province [24] 0 0
North Carolina
Country [25] 0 0
United States of America
State/province [25] 0 0
North Dakota
Country [26] 0 0
United States of America
State/province [26] 0 0
Ohio
Country [27] 0 0
United States of America
State/province [27] 0 0
Oklahoma
Country [28] 0 0
United States of America
State/province [28] 0 0
Oregon
Country [29] 0 0
United States of America
State/province [29] 0 0
Pennsylvania
Country [30] 0 0
United States of America
State/province [30] 0 0
South Carolina
Country [31] 0 0
United States of America
State/province [31] 0 0
Tennessee
Country [32] 0 0
United States of America
State/province [32] 0 0
Texas
Country [33] 0 0
United States of America
State/province [33] 0 0
Utah
Country [34] 0 0
United States of America
State/province [34] 0 0
Vermont
Country [35] 0 0
United States of America
State/province [35] 0 0
Virginia
Country [36] 0 0
United States of America
State/province [36] 0 0
Washington
Country [37] 0 0
United States of America
State/province [37] 0 0
Wisconsin
Country [38] 0 0
Austria
State/province [38] 0 0
Innsbruck
Country [39] 0 0
Austria
State/province [39] 0 0
Wien N/A
Country [40] 0 0
Belgium
State/province [40] 0 0
Bonheiden
Country [41] 0 0
Belgium
State/province [41] 0 0
Brussel
Country [42] 0 0
Belgium
State/province [42] 0 0
Gent
Country [43] 0 0
Belgium
State/province [43] 0 0
Leuven
Country [44] 0 0
Belgium
State/province [44] 0 0
Liège
Country [45] 0 0
Belgium
State/province [45] 0 0
Roeselare
Country [46] 0 0
Bulgaria
State/province [46] 0 0
Bulgaria
Country [47] 0 0
Bulgaria
State/province [47] 0 0
Pleven
Country [48] 0 0
Bulgaria
State/province [48] 0 0
Plovdiv
Country [49] 0 0
Bulgaria
State/province [49] 0 0
Rousse
Country [50] 0 0
Bulgaria
State/province [50] 0 0
Sofia
Country [51] 0 0
Canada
State/province [51] 0 0
Alberta
Country [52] 0 0
Canada
State/province [52] 0 0
British Columbia
Country [53] 0 0
Canada
State/province [53] 0 0
Manitoba
Country [54] 0 0
Canada
State/province [54] 0 0
Ontario
Country [55] 0 0
Canada
State/province [55] 0 0
Quebec
Country [56] 0 0
Canada
State/province [56] 0 0
Saskatchewan
Country [57] 0 0
Canada
State/province [57] 0 0
Toronto
Country [58] 0 0
Canada
State/province [58] 0 0
Windsor
Country [59] 0 0
Czech Republic
State/province [59] 0 0
Hradec Kralove
Country [60] 0 0
Czech Republic
State/province [60] 0 0
Litomerice
Country [61] 0 0
Czech Republic
State/province [61] 0 0
Ostrava
Country [62] 0 0
Czech Republic
State/province [62] 0 0
Èeské Budìjovice 1
Country [63] 0 0
Denmark
State/province [63] 0 0
Aalborg
Country [64] 0 0
Denmark
State/province [64] 0 0
Aarhus C.
Country [65] 0 0
Denmark
State/province [65] 0 0
Hvidovre
Country [66] 0 0
Denmark
State/province [66] 0 0
Odense C
Country [67] 0 0
France
State/province [67] 0 0
Amiens Cedex 1 80
Country [68] 0 0
France
State/province [68] 0 0
Bordeaux 33
Country [69] 0 0
France
State/province [69] 0 0
Clichy
Country [70] 0 0
France
State/province [70] 0 0
Lille Cedex
Country [71] 0 0
France
State/province [71] 0 0
Marseille Cedex 13
Country [72] 0 0
France
State/province [72] 0 0
Nice Cedex 3
Country [73] 0 0
France
State/province [73] 0 0
Paris
Country [74] 0 0
France
State/province [74] 0 0
Rouen
Country [75] 0 0
Germany
State/province [75] 0 0
Aachen
Country [76] 0 0
Germany
State/province [76] 0 0
Berlin Be
Country [77] 0 0
Germany
State/province [77] 0 0
Berlin
Country [78] 0 0
Germany
State/province [78] 0 0
Bochum
Country [79] 0 0
Germany
State/province [79] 0 0
Frankfurt
Country [80] 0 0
Germany
State/province [80] 0 0
Hamburg
Country [81] 0 0
Germany
State/province [81] 0 0
Hannover
Country [82] 0 0
Germany
State/province [82] 0 0
Heidelberg
Country [83] 0 0
Germany
State/province [83] 0 0
Herne
Country [84] 0 0
Germany
State/province [84] 0 0
Jena
Country [85] 0 0
Germany
State/province [85] 0 0
Kiel
Country [86] 0 0
Germany
State/province [86] 0 0
Magdeburg
Country [87] 0 0
Germany
State/province [87] 0 0
Minden
Country [88] 0 0
Germany
State/province [88] 0 0
Muenchen
Country [89] 0 0
Germany
State/province [89] 0 0
München
Country [90] 0 0
Germany
State/province [90] 0 0
Münster
Country [91] 0 0
Germany
State/province [91] 0 0
Neustadt
Country [92] 0 0
Germany
State/province [92] 0 0
Stade
Country [93] 0 0
Hungary
State/province [93] 0 0
Balatonfured
Country [94] 0 0
Hungary
State/province [94] 0 0
Budapest N/A
Country [95] 0 0
Hungary
State/province [95] 0 0
Budapest
Country [96] 0 0
Hungary
State/province [96] 0 0
Debrecen
Country [97] 0 0
Hungary
State/province [97] 0 0
Dunaujvaros
Country [98] 0 0
Hungary
State/province [98] 0 0
Gyulai Ut 18
Country [99] 0 0
Hungary
State/province [99] 0 0
Gyula
Country [100] 0 0
Hungary
State/province [100] 0 0
Gyõr
Country [101] 0 0
Hungary
State/province [101] 0 0
Miskolc
Country [102] 0 0
Hungary
State/province [102] 0 0
Mosonmagyarovar
Country [103] 0 0
Hungary
State/province [103] 0 0
Pécs
Country [104] 0 0
Hungary
State/province [104] 0 0
Siofok
Country [105] 0 0
Hungary
State/province [105] 0 0
Sopron
Country [106] 0 0
Hungary
State/province [106] 0 0
Szeged
Country [107] 0 0
Hungary
State/province [107] 0 0
Szekesfehervar
Country [108] 0 0
Hungary
State/province [108] 0 0
Szekszard
Country [109] 0 0
Hungary
State/province [109] 0 0
Szombathely
Country [110] 0 0
Hungary
State/province [110] 0 0
Veszprém
Country [111] 0 0
Hungary
State/province [111] 0 0
Zalaegerszeg
Country [112] 0 0
India
State/province [112] 0 0
Bangalore
Country [113] 0 0
India
State/province [113] 0 0
Chennai
Country [114] 0 0
India
State/province [114] 0 0
Hyderabad Andh Prad
Country [115] 0 0
India
State/province [115] 0 0
Hyderabad
Country [116] 0 0
India
State/province [116] 0 0
Jaipur
Country [117] 0 0
India
State/province [117] 0 0
Karnad
Country [118] 0 0
India
State/province [118] 0 0
Lucknow Gpo
Country [119] 0 0
India
State/province [119] 0 0
Ludhiana
Country [120] 0 0
India
State/province [120] 0 0
New Delhi
Country [121] 0 0
India
State/province [121] 0 0
Pune
Country [122] 0 0
India
State/province [122] 0 0
Vishakapatanam
Country [123] 0 0
Israel
State/province [123] 0 0
Afula
Country [124] 0 0
Israel
State/province [124] 0 0
Beer Sheva
Country [125] 0 0
Israel
State/province [125] 0 0
Beer Yaakov
Country [126] 0 0
Israel
State/province [126] 0 0
Haifa
Country [127] 0 0
Israel
State/province [127] 0 0
Hedera
Country [128] 0 0
Israel
State/province [128] 0 0
Jerusalem
Country [129] 0 0
Israel
State/province [129] 0 0
Kfar Sava
Country [130] 0 0
Israel
State/province [130] 0 0
Kiryat Bialik
Country [131] 0 0
Israel
State/province [131] 0 0
Nazareth
Country [132] 0 0
Israel
State/province [132] 0 0
Petah-Tikv
Country [133] 0 0
Israel
State/province [133] 0 0
Rechovot
Country [134] 0 0
Israel
State/province [134] 0 0
Tel Hashomer
Country [135] 0 0
Israel
State/province [135] 0 0
Tel-Aviv
Country [136] 0 0
Japan
State/province [136] 0 0
Bunkyo-Ku
Country [137] 0 0
Japan
State/province [137] 0 0
Bunkyo
Country [138] 0 0
Japan
State/province [138] 0 0
Chikushinoshi
Country [139] 0 0
Japan
State/province [139] 0 0
Fukuoka
Country [140] 0 0
Japan
State/province [140] 0 0
Hiroshima
Country [141] 0 0
Japan
State/province [141] 0 0
Kagoshima
Country [142] 0 0
Japan
State/province [142] 0 0
Kurashiki
Country [143] 0 0
Japan
State/province [143] 0 0
Kurume
Country [144] 0 0
Japan
State/province [144] 0 0
Nagoya
Country [145] 0 0
Japan
State/province [145] 0 0
Nishinomiya
Country [146] 0 0
Japan
State/province [146] 0 0
Okayama
Country [147] 0 0
Japan
State/province [147] 0 0
Osaka
Country [148] 0 0
Japan
State/province [148] 0 0
Sakura
Country [149] 0 0
Japan
State/province [149] 0 0
Sapporo-Shi
Country [150] 0 0
Japan
State/province [150] 0 0
Sapporo
Country [151] 0 0
Japan
State/province [151] 0 0
Tokyo N/A
Country [152] 0 0
Japan
State/province [152] 0 0
Tokyo
Country [153] 0 0
Japan
State/province [153] 0 0
Yokkaichi
Country [154] 0 0
Latvia
State/province [154] 0 0
Balvi
Country [155] 0 0
Latvia
State/province [155] 0 0
Daugavpils
Country [156] 0 0
Latvia
State/province [156] 0 0
Riga
Country [157] 0 0
Lithuania
State/province [157] 0 0
Kaunas
Country [158] 0 0
Lithuania
State/province [158] 0 0
Klaipeda
Country [159] 0 0
Lithuania
State/province [159] 0 0
Siauliai
Country [160] 0 0
Lithuania
State/province [160] 0 0
Vilnius Lt
Country [161] 0 0
Lithuania
State/province [161] 0 0
Vilnius
Country [162] 0 0
Netherlands
State/province [162] 0 0
Amsterdam
Country [163] 0 0
Netherlands
State/province [163] 0 0
Ede Gld
Country [164] 0 0
Netherlands
State/province [164] 0 0
Groningen
Country [165] 0 0
Netherlands
State/province [165] 0 0
Leiden
Country [166] 0 0
Netherlands
State/province [166] 0 0
Nieuwegein
Country [167] 0 0
Netherlands
State/province [167] 0 0
Rotterdam
Country [168] 0 0
New Zealand
State/province [168] 0 0
Auckland
Country [169] 0 0
New Zealand
State/province [169] 0 0
Christchurch
Country [170] 0 0
New Zealand
State/province [170] 0 0
Dunedin
Country [171] 0 0
New Zealand
State/province [171] 0 0
Hamilton
Country [172] 0 0
New Zealand
State/province [172] 0 0
Hastings
Country [173] 0 0
Poland
State/province [173] 0 0
Bialystok N/A
Country [174] 0 0
Poland
State/province [174] 0 0
Bydgoszcz N/A
Country [175] 0 0
Poland
State/province [175] 0 0
Czestochowa
Country [176] 0 0
Poland
State/province [176] 0 0
Elblag
Country [177] 0 0
Poland
State/province [177] 0 0
Gdansk N/A
Country [178] 0 0
Poland
State/province [178] 0 0
Gdansk
Country [179] 0 0
Poland
State/province [179] 0 0
Krakow N/A
Country [180] 0 0
Poland
State/province [180] 0 0
Krakow
Country [181] 0 0
Poland
State/province [181] 0 0
Kraków N/A
Country [182] 0 0
Poland
State/province [182] 0 0
Lodz
Country [183] 0 0
Poland
State/province [183] 0 0
Lublin
Country [184] 0 0
Poland
State/province [184] 0 0
Opole N/A
Country [185] 0 0
Poland
State/province [185] 0 0
Skierniewice
Country [186] 0 0
Poland
State/province [186] 0 0
Sopot
Country [187] 0 0
Poland
State/province [187] 0 0
Szczecin
Country [188] 0 0
Poland
State/province [188] 0 0
Torun
Country [189] 0 0
Poland
State/province [189] 0 0
Warszawa N/A
Country [190] 0 0
Poland
State/province [190] 0 0
Warszawa
Country [191] 0 0
Romania
State/province [191] 0 0
Bucuresti
Country [192] 0 0
Romania
State/province [192] 0 0
Cluj-Napoca
Country [193] 0 0
Romania
State/province [193] 0 0
Iasi
Country [194] 0 0
Romania
State/province [194] 0 0
Targu Mures
Country [195] 0 0
Romania
State/province [195] 0 0
Timisoara
Country [196] 0 0
Russian Federation
State/province [196] 0 0
Moscow
Country [197] 0 0
Russian Federation
State/province [197] 0 0
Novosibirsk
Country [198] 0 0
Russian Federation
State/province [198] 0 0
Omsk
Country [199] 0 0
Russian Federation
State/province [199] 0 0
Saint Petersburg
Country [200] 0 0
Russian Federation
State/province [200] 0 0
Smolensk
Country [201] 0 0
Russian Federation
State/province [201] 0 0
St Petersburg
Country [202] 0 0
Russian Federation
State/province [202] 0 0
St-Petersburg
Country [203] 0 0
Russian Federation
State/province [203] 0 0
Yaroslavl
Country [204] 0 0
Serbia
State/province [204] 0 0
Belgrade
Country [205] 0 0
Serbia
State/province [205] 0 0
Beograd
Country [206] 0 0
Serbia
State/province [206] 0 0
Nis
Country [207] 0 0
Serbia
State/province [207] 0 0
Zemun
Country [208] 0 0
Slovakia
State/province [208] 0 0
Bratislava
Country [209] 0 0
Slovakia
State/province [209] 0 0
Martin
Country [210] 0 0
Slovakia
State/province [210] 0 0
Nitra
Country [211] 0 0
Slovakia
State/province [211] 0 0
Nove Mesto Nad Vahom
Country [212] 0 0
Slovakia
State/province [212] 0 0
Presov
Country [213] 0 0
Slovakia
State/province [213] 0 0
Trnava
Country [214] 0 0
South Africa
State/province [214] 0 0
Cape Town West Cape
Country [215] 0 0
South Africa
State/province [215] 0 0
Cape Town
Country [216] 0 0
South Africa
State/province [216] 0 0
Durban N/A
Country [217] 0 0
South Africa
State/province [217] 0 0
Plumstead West Cape
Country [218] 0 0
South Africa
State/province [218] 0 0
Pretoria Gauteng
Country [219] 0 0
Sweden
State/province [219] 0 0
Göteborg
Country [220] 0 0
Sweden
State/province [220] 0 0
Stockholm
Country [221] 0 0
Ukraine
State/province [221] 0 0
Donetsk
Country [222] 0 0
Ukraine
State/province [222] 0 0
Ivano
Country [223] 0 0
Ukraine
State/province [223] 0 0
Kharkiv
Country [224] 0 0
Ukraine
State/province [224] 0 0
Kiev
Country [225] 0 0
Ukraine
State/province [225] 0 0
Kyiv
Country [226] 0 0
Ukraine
State/province [226] 0 0
Lviv
Country [227] 0 0
Ukraine
State/province [227] 0 0
Poltava
Country [228] 0 0
Ukraine
State/province [228] 0 0
Simferopol
Country [229] 0 0
Ukraine
State/province [229] 0 0
Vinnitsa
Country [230] 0 0
Ukraine
State/province [230] 0 0
Zhaporozhia 69104

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Janssen Research & Development, LLC
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Merck Sharp & Dohme LLC
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the safety and efficacy of golimumab administered
subcutaneously (under the skin) injections in maintenance therapy.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00488631
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00488631